文献速递临床试验与 GCP

救护车中应用硝酸甘油贴片治疗急性卒中的多中心随机试验(MR ASAP):一项随机对照试验的研究方案

Multicentre Randomised trial of Acute Stroke treatment in the Ambulance with a nitroglycerin Patch (MR ASAP): study protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2019-06-26

MR ASAP是一项III期多中心随机开放标签盲法终点评估试验,计划纳入1400例疑似卒中且收缩压≥140 mmHg的成人患者,在院前发病3小时内随机接受经皮硝酸甘油贴片(5 mg/天,持续24小时)或标准治疗,主要结局为90天改良Rankin量表评分,采用序贯逻辑回归分析。

要点

  • 院前发病3小时内经皮硝酸甘油5 mg/天持续24小时,对照为标准治疗。
  • 主要结局为90天mRS评分,用序贯逻辑回归分析。
  • 次要结局包括入院血压、侧支循环、24小时NIHSS、90天死亡和不良结局(mRS 3-6分)。

核心结论

  • MR ASAP将评估在静脉溶栓和血管内治疗率高的环境下,极早期给予硝酸甘油能否改善卒中结局。
  • 若早期经皮硝酸甘油治疗被证明有效,这一低成本治疗可 readily 纳入日常临床实践。

研究设计与样本

  • III期、多中心、随机、开放标签、盲法终点评估临床试验,在荷兰开展,采用延迟知情同意程序。
  • 计划纳入1400例疑似卒中且收缩压≥140 mmHg的成人患者,随机接受经皮硝酸甘油(5 mg/天)或标准治疗。
  • 院前由急救人员自发病3小时内开始给药,持续24小时。
  • 主要结局为90天改良Rankin量表(mRS)评分,采用序贯逻辑回归分析。

主要发现

  • 次要结局包括入院时血压和侧支循环、24小时美国国立卫生研究院卒中量表(NIHSS)评分的神经功能缺损、90天死亡率和不良结局(mRS 3-6分)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Some studies have suggested that transdermal administration of glyceryl trinitrate (GTN; nitroglycerin) in the first few hours after symptom onset increases the chance of a favourable outcome after ischaemic stroke or intracerebral haemorrhage, possibly through an increase in intracranial collateral blood flow and a reduction in blood pressure. The Multicentre Randomised trial of Acute Stroke treatment in the Ambulance with a nitroglycerin Patch (MR ASAP) aims to assess the effect of transdermal GTN, started within 3 h after stroke onset in the prehospital setting, on functional outcome at 90 days in patients with acute ischaemic stroke or intracerebral haemorrhage. METHODS: MR ASAP is a phase III, multicentre, randomised, open-label clinical trial with a blinded outcome assessment. A total of 1400 adult patients with suspected stroke and a systolic blood pressure ≥ 140 mmHg will be randomised to transdermal GTN (5 mg/day), administered as a transdermal patch by paramedics in the prehospital setting within 3 h of stroke onset and continued for 24 h or to standard care. The primary outcome is the score on the modified Rankin Scale (mRS) at 90 days, analysed with ordinal logistic regression. Secondary outcomes include blood pressure and collateral circulation at hospital admission, neurological deficit measured with the National Institutes of Health Stroke Scale at 24 h, and mortality and poor outcome (mRS score 3 to 6) at 90 days. This trial will be conducted in the Netherlands and will use a deferred consent procedure. The trial is part of the Collaboration for New Treatments of Acute Stroke (CONTRAST) programme. DISCUSSION: MR ASAP will assess whether very early administration of GTN improves outcome after stroke in a setting where rates of intravenous thrombolysis and endovascular treatment for acute ischaemic stroke are high. The deferred consent procedure facilitates prompt GTN treatment and will prevent delay to revascularisation therapies. If early transdermal GTN treatment proves to be effective, this low-cost treatment can be readily implemented into daily clinical practice. TRIAL REGISTRATION: ISRCTN Registry, ISRCTN99503308 . Registered on 2 January 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. van den Berg SA, Dippel DWJ, Hofmeijer J, et al. Multicentre Randomised trial of Acute Stroke treatment in the Ambulance with a nitroglycerin Patch (MR ASAP): study protocol for a randomised controlled trial. Trials. 2019. PMID: 31242931. doi:10.1186/s13063-019-3419-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。